Hua Yuan Zheng Quan·2026-02-26 07:52Investment Rating - The report assigns a "Buy" rating for China Life Insurance, indicating a positive outlook based on strong individual insurance sales capabilities and good investment performance [5]. Core Insights - China Life's Q3 revenue and net profit attributable to shareholders grew by 54.8% and 91.5% year-on-year, reaching CNY 298.7 billion and CNY 126.9 billion, respectively, which boosted the year-to-date revenue and net profit growth rates to 25.9% and 60.5% [5][10]. - The company's net assets attributable to shareholders increased by 22.8% to CNY 625.8 billion by the end of Q3, outperforming peers [8]. - The new business value (NBV) grew by 41.8% year-on-year, and the total investment return rate increased by 104 basis points to 6.42% [5][7]. Financial Performance - For the first three quarters of 2025, total investment income rose by 41% to CNY 368.6 billion, with a total investment return rate of 6.42% [7][10]. - The net profit for Q3 2025 reached CNY 126.9 billion, a significant increase from CNY 66.2 billion in Q3 2024, driven by reduced insurance service costs and strong new policy sales [8][10]. - The company has shown a strong improvement in new policy sales, with a year-on-year growth rate of 52.5% in Q3 2025 [8]. Earnings Forecast and Valuation - The report forecasts China Life's net profit for 2025-2027 to be CNY 153.0 billion, CNY 174.2 billion, and CNY 196.1 billion, with year-on-year growth rates of 43%, 14%, and 13% respectively [10]. - The estimated embedded value per share for 2025-2027 is projected to be CNY 56.0, CNY 61.7, and CNY 67.3, with current price-to-embedded value (P/EV) ratios of 0.55, 0.50, and 0.46 [10].